All Stories

  1. Quinazolinone-Based PqsR Modulators Suppress Quorum-Sensing–Driven Virulence in Pseudomonas aeruginosa

    Article • ACS Infectious Diseases, February 2026, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  2. Oxyprenyl–chalcones as antibacterial hits: design of experiments-optimized synthesis, antibacterial evaluation, early drug-like profiling and biodegradability prediction

    Article • RSC Medicinal Chemistry, January 2026, Royal Society of Chemistry

    Dr Stefania Butini

  3. Unveiling Wound Healing Properties of Biostimulated Walnut Kernel Extracts via Epithelial Mesenchymal Transition: Switching a Nutritional Matrix into a Therapeutic Remedy

    Article • Antioxidants, September 2025, MDPI AG

    Dr Stefania Butini

  4. A Focus on Natural Autophagy Modulators as Potential Host‐Directed Weapons Against Emerging and Re‐Emerging Viruses

    Article • Medicinal Research Reviews, July 2025, Wiley

    Dr Stefania Butini

  5. Discovery of p-Trifluoromethylbenzohydrazide Derivatives as Potent Antiviral Agents against Monkeypox Virus

    Article • ACS Medicinal Chemistry Letters, April 2025, American Chemical Society (ACS)

    Rita Berisio, Dr Stefania Butini

  6. A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients

    Article • Biomedicine & Pharmacotherapy, May 2024, Elsevier

    Dr Stefania Butini

  7. Metalloenzyme Inhibitors against Zoonotic Infections: Focus on Leishmania and Schistosoma

    Article • ACS Infectious Diseases, April 2024, American Chemical Society (ACS)

    Dr Stefania Butini

  8. Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization

    Article • Journal of Medicinal Chemistry, January 2024, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  9. Synthetic derivatives of natural cinnamic acids as potential anti‐colorectal cancer agents

    Article • Chemical Biology & Drug Design, December 2023, Wiley

    PhD Francesca F Aiello , Dr Stefania Butini

  10. Nutritionally enriched tomatoes ( Solanum lycopersicum L.) grown with wood distillate: chemical and biological characterization for quality assessment

    Article • Journal of Food Science, November 2023, Wiley

    Dr Stefania Butini

  11. Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains

    Article • Molecules, September 2023, MDPI AG

    Dr Simone Brogi, Dr Stefania Butini

  12. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors

    Article • International Journal of Molecular Sciences, September 2022, MDPI AG

    Dr Stefania Butini

  13. Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure-Based Drug Discovery Approach

    Article • ACS Infectious Diseases, July 2022, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  14. In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro)

    Article • Computation, May 2022, MDPI AG

    Dr Simone Brogi, Dr Stefania Butini

  15. Design and Synthesis of Oligopeptidic Parvulin Inhibitors

    Article • ChemMedChem, April 2022, Wiley

    Dr Simone Brogi, Dr Stefania Butini

  16. Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis

    Article • Cells, April 2022, MDPI AG

    Dr Stefania Butini

  17. Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases

    Article • Molecules, April 2022, MDPI AG

    Dr Simone Brogi, Dr Stefania Butini

  18. Extra Virgin Olive Oil Extracts of Indigenous Southern Tuscany Cultivar Act as Anti-Inflammatory and Vasorelaxant Nutraceuticals

    Article • Antioxidants, February 2022, MDPI AG

    Dr Stefania Butini

  19. Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

    Article • Cells, January 2022, MDPI AG

    Dr Stefania Butini

  20. Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity

    Article • Molecules, January 2022, MDPI AG

    Dr Stefania Butini

  21. Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity

    Article • European Journal of Medicinal Chemistry, April 2021, Elsevier

    Dr Stefania Butini

  22. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists

    Article • Journal of Medicinal Chemistry, August 2020, American Chemical Society (ACS)

    Dr Stefania Butini

  23. Retinitis Pigmentosa and Retinal Degenerations: Deciphering Pathways and Targets for Drug Discovery and Development

    Article • ACS Chemical Neuroscience, June 2020, American Chemical Society (ACS)

    Dr Stefania Butini

  24. Ionotropic Glutamate Receptor GluA2 in Complex with Bicyclic Pyrimidinedione-Based Compounds: When Small Compound Modifications Have Distinct Effects on Binding Interactions

    Article • ACS Chemical Neuroscience, June 2020, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  25. Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials

    Article • Current Topics in Medicinal Chemistry, April 2020, Bentham Science Publishers

    Dr Simone Brogi, Dr sandra gemma, Dr Stefania Butini, Stefano Federico

  26. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles

    Article • Molecules, November 2019, MDPI AG

    Dr Simone Brogi, Dr Stefania Butini

  27. Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas

    Article • Medicinal Research Reviews, November 2019, Wiley

    Dr Stefania Butini

  28. Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents

    Article • ACS Infectious Diseases, November 2019, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  29. Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors

    Article • Medicinal Chemistry, October 2019, Bentham Science Publishers

    Dr Simone Brogi, Dr Stefania Butini

  30. Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems

    Article • European Journal of Medicinal Chemistry, September 2019, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  31. Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases

    Article • Journal of Medicinal Chemistry, August 2019, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  32. Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach

    Article • Frontiers in Chemistry, August 2019, Frontiers

    Dr Simone Brogi, Dr Stefania Butini

  33. Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II)

    Article • Bioorganic Chemistry, August 2019, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  34. Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors

    Article • Drug Discovery Today, July 2019, Elsevier

    Dr Stefania Butini

  35. A Light in the Dark: State of the Art and Perspectives in Optogenetics and Optopharmacology for Restoring Vision

    Article • Future Medicinal Chemistry, March 2019, Taylor & Francis

    Dr Simone Brogi, Dr Stefania Butini

  36. Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders

    Article • ACS Medicinal Chemistry Letters, February 2019, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  37. Dealing with schistosomiasis: Current drug discovery strategies

    Article • January 2019, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  38. Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents

    Article • European Journal of Medicinal Chemistry, January 2019, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  39. Author Correction: The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity

    Article • Scientific Reports, December 2018, Springer Science + Business Media

    Dr Stefania Butini

  40. A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents

    Article • Tetrahedron Letters, November 2018, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  41. Synthetic studies toward bicyclic endoperoxides presenting polar side chains

    Article • Tetrahedron Letters, October 2018, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  42. Development of a Multiplexed Activity-Based Protein Profiling Assay to Evaluate Activity of Endocannabinoid Hydrolase Inhibitors

    Article • ACS Chemical Biology, September 2018, American Chemical Society (ACS)

    Dr Stefania Butini

  43. Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain

    Article • ChemMedChem, August 2018, Wiley

    Dr Simone Brogi, Dr Stefania Butini

  44. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies

    Article • European Journal of Medicinal Chemistry, July 2018, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  45. iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated α-tubulin defect which improves after iHDAC6 treatment in Rett syndrome

    Article • Experimental Cell Research, May 2018, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  46. Author Correction: The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity

    Article • Scientific Reports, March 2018, Nature

    Dr Stefania Butini

  47. Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]- N -[(piperidin-4-yl)methyl]methanamine (MMV019918) and a...

    Article • European Journal of Medicinal Chemistry, March 2018, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  48. (S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation

    Article • Journal of Medicinal Chemistry, February 2018, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini, Dr Simone Brogi

  49. Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages

    Article • ChemMedChem, February 2018, Wiley

    Dr Simone Brogi, Davide M Ferraris, Dr Stefania Butini

  50. Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation

    Article • ChemMedChem, November 2017, Wiley

    Dr Stefania Butini, Dr Simone Brogi

  51. The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity

    Article • Scientific Reports, September 2017, Nature

    Dr Stefania Butini

  52. First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents

    Article • European Journal of Medicinal Chemistry, June 2017, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  53. Structural characterization of Giardia duodenalis thioredoxin reductase ( g TrxR) and computational analysis of its interaction with NBDHEX

    Article • European Journal of Medicinal Chemistry, April 2017, Elsevier

    Dr Simone Brogi, Dr sandra gemma, Dr Stefania Butini

  54. Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity

    Article • Frontiers in Chemistry, February 2017, Frontiers

    Dr Simone Brogi, Dr Stefania Butini

  55. Identification of novel fluorescent probes preventing PrPSc replication in prion diseases

    Article • European Journal of Medicinal Chemistry, November 2016, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  56. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases

    Article • Frontiers in Neuroscience, October 2016, Frontiers

    Dr Stefania Butini, Prof. Dr. Dr. h.c. Holger Stark, Dr Simone Brogi

  57. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies

    Article • Future Medicinal Chemistry, September 2016, Future Science

    Dr Simone Brogi, Dr Stefania Butini

  58. Development of novel cyclic peptides as pro-apoptotic agents

    Article • European Journal of Medicinal Chemistry, July 2016, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  59. Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine–induced apoptosis in neuroblastoma cells

    Article • Investigational New Drugs, June 2016, Springer Science + Business Media

    Dr Stefania Butini

  60. Multiple Targeting Approaches on Histamine H3 Receptor Antagonists

    Article • Frontiers in Neuroscience, May 2016, Frontiers

    Dr Stefania Butini

  61. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells

    Article • International Journal of Oncology, May 2016, Spandidos Publications

    Dr Stefania Butini

  62. Polypharmacology of dopamine receptor ligands

    Article • Progress in Neurobiology, May 2016, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  63. Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors

    Article • Journal of Enzyme Inhibition and Medicinal Chemistry, April 2016, Taylor & Francis

    Dr Simone Brogi, Dr Stefania Butini

  64. Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain

    Article • Journal of Medicinal Chemistry, March 2016, American Chemical Society (ACS)

    Dr Simone Brogi, Dr Stefania Butini

  65. In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors

    Article • Journal of Molecular Graphics and Modelling, March 2016, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  66. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15

    Article • Investigational New Drugs, February 2016, Springer Science + Business Media

    Dr Stefania Butini

  67. Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs

    Article • Tetrahedron Letters, February 2016, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  68. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease

    Article • Progress in Neurobiology, January 2016, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  69. Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition

    Article • RSC Advances, January 2016, Royal Society of Chemistry

    Dr Simone Brogi, Dr Stefania Butini

  70. Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.

    Article • Journal of Cancer, January 2016, Ivyspring International Publisher

    Dr Stefania Butini

  71. Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents

    Article • Bioorganic & Medicinal Chemistry Letters, November 2015, Elsevier

    Dr Simone Brogi, Dr Stefania Butini

  72. Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation

    Article • European Journal of Medicinal Chemistry, October 2015, Elsevier

    Dr Simone Brogi, Dr Stefania Butini, Dr Tsutomu Inokuchi

  73. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells

    Article • Cancer Biology & Therapy, September 2015, Taylor & Francis

    Dr Stefania Butini

  74. Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors

    Article • Chemical Biology & Drug Design, September 2015, Wiley

    Dr Stefania Butini

  75. Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats

    Article • Neuropsychopharmacology, September 2015, Nature

    Dr Stefania Butini

  76. Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents

    Article • European Journal of Medicinal Chemistry, September 2015, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  77. Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines

    Article • Molecular Medicine Reports, May 2015, Spandidos Publications

    Dr Stefania Butini

  78. Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking

    Article • Scientific Reports, May 2015, Springer Science + Business Media

    Dr Stefania Butini, Dr Simone Brogi, Dr sandra gemma

  79. Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer’s Disease

    Article • Mini-Reviews in Medicinal Chemistry, April 2015, Bentham Science Publishers

    Dr Simone Brogi, Dr Stefania Butini

  80. Synthetic spirocyclic endoperoxides: new antimalarial scaffolds

    Article • MedChemComm, January 2015, Royal Society of Chemistry

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  81. Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors

    Article • RSC Advances, January 2015, Royal Society of Chemistry

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  82. Targeting Dopamine D 3 and Serotonin 5-HT 1A and 5-HT 2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies

    Article • Journal of Medicinal Chemistry, November 2014, American Chemical Society (ACS)

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  83. Rational design of the first difluorostatone-based PfSUB1 inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, August 2014, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  84. 831: Induction of apoptosis by pyrrolo-1,5-benzoxazepines in oral squamous carcinoma cells

    Article • European Journal of Cancer, July 2014, Elsevier

    Dr Stefania Butini

  85. Disease-Modifying Anti-Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering withβ-Amyloid Aggregation

    Article • CNS Neuroscience & Therapeutics, June 2014, Wiley

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  86. HCV-targeted Antivirals: Current Status and Future Challenges

    Article • Current Pharmaceutical Design, May 2014, Bentham Science Publishers

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  87. Retraction notice to “PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines” [Eur. J. Pharmacol. 714(1–3) (2013) 379–387]

    Article • European Journal of Pharmacology, April 2014, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  88. The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells

    Article • Biochemical Pharmacology, February 2014, Elsevier

    Dr Stefania Butini

  89. From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum

    Article • RSC Advances, January 2014, Royal Society of Chemistry

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  90. Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation

    Article • ACS Medicinal Chemistry Letters, December 2013, American Chemical Society (ACS)

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  91. A stereoselective approach to peptidomimetic BACE1 inhibitors

    Article • European Journal of Medicinal Chemistry, December 2013, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  92. A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues

    Article • Tetrahedron Letters, September 2013, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  93. RETRACTED: PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines

    Article • European Journal of Pharmacology, August 2013, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  94. The Structural Evolution of β-Secretase Inhibitors: A Focus on the Development of Small-Molecule Inhibitors

    Article • Current Topics in Medicinal Chemistry, July 2013, Bentham Science Publishers

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  95. Synthesis and structure–activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds

    Article • European Journal of Medicinal Chemistry, May 2013, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini, dr gianfranco caselli

  96. A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides

    Article • Tetrahedron Letters, March 2013, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  97. Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies

    Article • Bioorganic & Medicinal Chemistry Letters, January 2013, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  98. Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties

    Article • Bioorganic & Medicinal Chemistry Letters, January 2013, Elsevier

    Dr sandra gemma, Dr Stefania Butini, Professor Walter Cabri

  99. Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents

    Article • Journal of Medicinal Chemistry, December 2012, American Chemical Society (ACS)

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini, Dr Francesco Tadini-Buoninsegni

  100. A Straightforward Approach for Engineering Efficacy and Selectivity at GPCRs

    Article • Journal of Medicinal Chemistry, August 2012, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  101. Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases

    Article • Journal of Medicinal Chemistry, August 2012, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini, Professor Walter Cabri

  102. Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure–Activity Relationships, in Vivo Studies, and Preliminary Toxicity Profiling

    Article • Journal of Medicinal Chemistry, August 2012, American Chemical Society (ACS)

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  103. Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1

    Article • Bioorganic & Medicinal Chemistry Letters, August 2012, Elsevier

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  104. The Ca2+-ATPase (SERCA1) Is Inhibited by 4-Aminoquinoline Derivatives through Interference with Catalytic Activation by Ca2+, Whereas the ATPase E2 State Remains Functional

    Article • Journal of Biological Chemistry, September 2011, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Francesco Tadini-Buoninsegni, Dr sandra gemma, Dr Stefania Butini

  105. Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues

    Article • Journal of Medicinal Chemistry, August 2011, American Chemical Society (ACS)

    Dr sandra gemma, Dr Simone Brogi, Dr Stefania Butini

  106. Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1 H -Cyclopentapyrimidin-2,4(1 H ,3 H )-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization

    Article • Journal of Medicinal Chemistry, July 2011, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  107. Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants

    Article • Bioorganic & Medicinal Chemistry Letters, July 2011, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  108. Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase

    Article • Bioorganic & Medicinal Chemistry Letters, May 2011, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  109. Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies

    Article • Journal of Medicinal Chemistry, March 2011, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  110. Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils

    Article • Organic & Biomolecular Chemistry, January 2011, Royal Society of Chemistry

    Dr sandra gemma, Dr Stefania Butini

  111. PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors and potentiates TRAIL-mediated apoptosis in multiple myeloma cells

    Article • British Journal of Cancer, December 2010, Nature

    Dr Stefania Butini

  112. Malaria Chemotherapy: Recent Advances in Drug Development

    Article • Recent Patents on Anti-Infective Drug Discovery, November 2010, Bentham Science Publishers

    Dr sandra gemma, Dr Stefania Butini

  113. Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D 3 and Serotonin 5-HT 1A and 5-HT 2A Receptors

    Article • Journal of Medicinal Chemistry, June 2010, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  114. Synthesis of Dihydroplakortin, 6- epi -Dihydroplakortin, and Their C10-Desethyl Analogues

    Article • The Journal of Organic Chemistry, April 2010, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  115. The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium

    Article • Current Topics in Medicinal Chemistry, April 2010, Bentham Science Publishers

    Dr sandra gemma, Dr Stefania Butini

  116. Inhibition of SERCA1 by a Novel Antimalarial Compound

    Article • Biophysical Journal, January 2010, Elsevier

    Dr sandra gemma, Dr Stefania Butini, Dr Francesco Tadini-Buoninsegni

  117. Novel, Potent, and Selective Quinoxaline-Based 5-HT 3 Receptor Ligands. 1. Further Structure−Activity Relationships and Pharmacological Characterization

    Article • Journal of Medicinal Chemistry, November 2009, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  118. The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia

    Article • Cancer Research, October 2009, American Association for Cancer Research (AACR)

    Dr Stefania Butini

  119. Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials

    Article • Tetrahedron Letters, October 2009, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  120. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure–activity relationship studies

    Article • Bioorganic & Medicinal Chemistry, August 2009, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  121. Specific Targeting of Peripheral Serotonin 5-HT 3 Receptors. Synthesis, Biological Investigation, and Structure−Activity Relationships

    Article • Journal of Medicinal Chemistry, June 2009, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  122. Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations

    Article • Journal of Medicinal Chemistry, February 2009, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  123. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells

    Article • Biochemical Pharmacology, February 2009, Elsevier

    Dr Stefania Butini

  124. Combining 4-Aminoquinoline- and Clotrimazole-Based Pharmacophores toward Innovative and Potent Hybrid Antimalarials

    Article • Journal of Medicinal Chemistry, January 2009, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  125. Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D 3 and Serotonin 5-HT 1A and 5-HT 2A Receptors: Design, Synthesis, and Effects on Behavior

    Article • Journal of Medicinal Chemistry, January 2009, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  126. An Efficient Approach to Chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as Peptidomimetic Scaffolds

    Article • The Journal of Organic Chemistry, November 2008, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  127. 1 H -Cyclopentapyrimidine-2,4(1 H ,3 H )-dione-Related Ionotropic Glutamate Receptors Ligands. Structure−Activity Relationships and Identification of Potent and Selective iGluR5 Modulators

    Article • Journal of Medicinal Chemistry, October 2008, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  128. Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity

    Article • Bioorganic & Medicinal Chemistry Letters, October 2008, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  129. Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the “primer grip” region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants

    Article • Biochemical Pharmacology, July 2008, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  130. Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors

    Article • Journal of Medicinal Chemistry, June 2008, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  131. Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives

    Article • Tetrahedron Letters, March 2008, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  132. Design, Synthesis, and Structure–Activity Relationship Studies of 4-Quinolinyl- and 9-Acrydinylhydrazones as Potent Antimalarial Agents

    Article • Journal of Medicinal Chemistry, March 2008, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  133. Clotrimazole Scaffold as an Innovative Pharmacophore Towards Potent Antimalarial Agents: Design, Synthesis, and Biological and Structure–Activity Relationship Studies

    Article • Journal of Medicinal Chemistry, March 2008, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  134. A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin

    Article • Journal of Molecular Medicine, February 2008, Springer Science + Business Media

    Dr Stefania Butini

  135. Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling

    Article • Bioorganic & Medicinal Chemistry Letters, July 2007, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  136. Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold:  Exploring an Innovative Pharmacophore

    Article • Journal of Medicinal Chemistry, February 2007, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  137. Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains

    Article • Bioorganic & Medicinal Chemistry Letters, October 2006, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  138. Discovery of Huperzine A−Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Midgorge Recognition Sites

    Article • Journal of Medicinal Chemistry, June 2006, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  139. Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis, and Biological Evaluation of Novel, Potent, and Broad Spectrum NNRTIs with Antiviral Activity

    Article • Journal of Medicinal Chemistry, November 2005, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  140. Specific Targeting of Hepatitis C Virus NS3 RNA Helicase. Discovery of the Potent and Selective Competitive Nucleotide-Mimicking Inhibitor QU663 †

    Article • Biochemistry, July 2005, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  141. Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target

    Article • Journal of Medicinal Chemistry, June 2005, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  142. Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitors †

    Article • Journal of Medicinal Chemistry, March 2005, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  143. Novel Atypical Antipsychotic Agents:  Rational Design, an Efficient Palladium-Catalyzed Route, and Pharmacological Studies

    Article • Journal of Medicinal Chemistry, March 2005, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  144. Pyrrolo[1,3]benzothiazepine-Based Serotonin and Dopamine Receptor Antagonists. Molecular Modeling, Further Structure−Activity Relationship Studies, and Identification of Novel Atypical Antipsychotic Agents

    Article • Journal of Medicinal Chemistry, January 2004, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  145. Synthesis and Pharmacological Evaluation of Potent and Highly Selective D 3 Receptor Ligands:  Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D 3 /D 2 Receptors †

    Article • Journal of Medicinal Chemistry, August 2003, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini, PhD Francesca F Aiello

  146. A Palladium-Catalyzed Synthetic Approach to New Huperzine A Analogues Modified at the Pyridone Ring.

    Article • ChemInform, May 2003, Wiley

    Dr sandra gemma, Dr Stefania Butini

  147. Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia

    Article • Expert Opinion on Therapeutic Patents, April 2003, Informa Healthcare

    Dr Stefania Butini

  148. Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases

    Article • Current Pharmaceutical Design, March 2003, Bentham Science Publishers

    Dr Stefania Butini

  149. A palladium-catalyzed synthetic approach to new Huperzine A analogues modified at the pyridone ring

    Article • Tetrahedron, January 2003, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  150. Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia

    Article • Expert Opinion on Therapeutic Patents, January 2003, Informa Healthcare

    Dr Stefania Butini

  151. Polycondensed heterocycles. Part 12: An approach to the synthesis of 2-acetyl-1′-methyl-1,2,3,4-tetrahydrospiro[isoquinoline-1,4′-pyrrolidine]-2′-one

    Article • Tetrahedron, May 2002, Elsevier

    Dr sandra gemma, Dr Stefania Butini

  152. Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structure−Activity Relationship, Molecular Modeling, and Biological Studies

    Article • Journal of Medicinal Chemistry, January 2002, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini

  153. Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT 3 Receptor Agonists:  Synthesis, Further Structure−Activity Relationships, and Biological Studies

    Article • Journal of Medicinal Chemistry, October 1999, American Chemical Society (ACS)

    Dr sandra gemma, Dr Stefania Butini